Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report)’s share price dropped 6.9% during trading on Wednesday . The stock traded as low as $8.72 and last traded at $8.78. 1,120 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 140,596 shares. The stock had previously closed at $9.43.
Analyst Ratings Changes
SGIOY has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Finally, The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy”.
Read Our Latest Analysis on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Price Performance
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.47% and a net margin of 46.67%.The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million. As a group, sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.79 earnings per share for the current fiscal year.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Featured Stories
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
- Why the Landlord of the AI Boom Could Outlast the Chipmakers
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
